24 Participants Needed

Losartan for Sickle Cell Disease

ON
AP
Overseen ByAmanda Pfeiffer
Age: Any Age
Sex: Any
Trial Phase: Phase 2
Sponsor: Children's Hospital Medical Center, Cincinnati
Must be taking: Sickle cell therapies
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 3 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing losartan, a blood pressure medication, in patients aged 6 and older with Sickle Cell Disease. The goal is to see if it can safely reduce fluid buildup in the body over time.

Are You a Good Fit for This Trial?

This trial is for patients 6 years or older with Sickle Cell Disease (SCD), specifically HbSS or Sbeta0-thalassemia. They must be able to undergo heart imaging without sedation and have been on a stable dose of certain SCD therapies for 3 months. Excluded are those on chronic transfusion therapy, with severe kidney issues, pregnant women not using contraception, and others listed in the exclusion criteria.

Inclusion Criteria

I have been on a stable dose of medication for sickle cell disease for 3 months.
You are able to undergo an echocardiogram without needing to be asleep or numb.
I am 6 years old or older.
See 2 more

Exclusion Criteria

My sickle cell disease genotype is not listed in the study's accepted types.
Inability to cooperate with CMR or echocardiography imaging
You are allergic to angiotensin receptor II blockers.
See 11 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive oral losartan daily for 12 months to assess its efficacy in stabilizing or decreasing extracellular volume fraction (ECV) in Sickle Cell Disease

12 months
Regular visits as per study protocol

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessments of myocardial fibrosis and exercise capacity

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Losartan
Trial Overview The study tests Losartan's safety and effectiveness in stabilizing or reducing heart muscle scarring over 12 months in SCD patients. It's an open-label pilot phase II trial enrolling 24 participants to gather preliminary data.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: LosartanExperimental Treatment1 Intervention

Losartan is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Cozaar for:
🇪🇺
Approved in European Union as Cozaar for:
🇨🇦
Approved in Canada as Cozaar for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Children's Hospital Medical Center, Cincinnati

Lead Sponsor

Trials
844
Recruited
6,566,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security